Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc. demonstrated strong financial performance with a 25% increase in top-line revenue in Q4, driven by a 17% growth in volume and a 5% increase in average selling prices (ASPs), alongside record revenues from patient and digital solutions. The company maintained a positive trend in Q3, achieving a 21% top-line growth and recording its highest cash collections to date, indicating robust demand for its testing services. Additionally, CareDx's strategic expansion of its sales force is expected to further enhance volume growth, as reflected in a significant increase in kidney surveillance volumes and raised revenue estimates for 2026 and 2027, which now sit at $433 million and $485 million, respectively.

Bears say

CareDx Inc. has projected a negative revenue impact of $7.5 million in its 2026 guidance, primarily due to anticipated changes in reimbursement policies that could significantly affect its testing services. In Q3'25, the company's testing volume growth fell short of expectations, with 50,000 tests recorded, reflecting a seasonal slowdown despite a year-over-year increase in surveillance testing. Additionally, CareDx's stock trades at a concerning valuation of 1.4x and 1.7x its 2026 revenue estimates, considerably below historical averages of 3-7x and well behind current leaders in the diagnostics sector, indicating potential challenges in sustaining market competitiveness and profitability.

CareDx (CDNA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 6 analysts, CareDx (CDNA) has a Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.